Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Among authors: elmets c. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma.
Bagot M, Dalle S, Sokol L, Tsianakas A, Musiek A, Ortiz-Romero PL, Poligone B, Duvic M, Elmets C, Leoni M, Dwyer K, Ito T, Herr F, Kim YH. Bagot M, et al. Among authors: elmets c. Dermatol Ther. 2022 Aug;35(8):e15634. doi: 10.1111/dth.15634. Epub 2022 Jun 28. Dermatol Ther. 2022. PMID: 35695215 Free PMC article. No abstract available.
Secukinumab (AIN-457) for the treatment of Psoriasis.
Jaleel T, Elmets C, Weinkle A, Kassira S, Elewski B. Jaleel T, et al. Among authors: elmets c. Expert Rev Clin Pharmacol. 2016;9(2):187-202. doi: 10.1586/17512433.2016.1129894. Expert Rev Clin Pharmacol. 2016. PMID: 26647300 Review.
CYP11A1‑derived vitamin D hydroxyderivatives as candidates for therapy of basal and squamous cell carcinomas.
Slominski AT, Brożyna AA, Kim TK, Elsayed MM, Janjetovic Z, Qayyum S, Slominski RM, Oak ASW, Li C, Podgorska E, Li W, Jetten AM, Tuckey RC, Tang EKY, Elmets C, Athar M. Slominski AT, et al. Among authors: elmets c. Int J Oncol. 2022 Aug;61(2):96. doi: 10.3892/ijo.2022.5386. Epub 2022 Jul 1. Int J Oncol. 2022. PMID: 35775377 Free PMC article.
276 results